Mok Oh
Impact in
- Gastroenterology top 5%
- Gastrointestinal Tumor Research and Treatment
- Oncology top 10%
- Pancreatic and Hepatic Oncology Research
Papers in
- Co-authors
- Ivo Abraham (15 shared papers)Ali McBride (12 shared papers)Jennifer Martin (4 shared papers)Joanne Jeter (5 shared papers)Kohei Shitara (3 shared papers)Jung Wook Park (2 shared papers)Peter C. Enzinger (1 shared paper)Rui‐Hua Xu (1 shared paper)
- Journals
- Journal of Clinical Oncology (8 papers)ESMO Open (2 papers)JNCI Journal of the National Cancer Institute (1 paper)Expert Opinion on Drug Safety (1 paper)The Prostate (1 paper)
- Partner nations
- United StatesJapanBelgium
In The Last Decade
Mok Oh
23 papers receiving 608 citations
Hit Papers
Peers
Comparison fields: 5 of 65
- Gastroenterology 91
- Oncology 263
- Pulmonary and Respiratory Medicine 300
- Neurology 75
- Cancer Research 108
Countries citing papers authored by Mok Oh
This map shows the geographic impact of Mok Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mok Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mok Oh more than expected).
Fields of papers citing papers by Mok Oh
This network shows the impact of papers produced by Mok Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mok Oh. The network helps show where Mok Oh may publish in the future.
Co-authors
The 25 scholars most cited alongside Mok Oh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 25 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 342 |
| 2 | 2019 | 90 | |
| 3 | 2018 | 86 | |
| 4 | 2018 | 24 | |
| 5 | 2020 | 14 | |
| 6 | 2020 | 12 | |
| 7 | 2024 | 10 | |
| 8 | 2022 | 7 | |
| 9 | 2020 | 5 | |
| 10 | 2023 | 5 | |
| 11 | 2022 | 4 | |
| 12 | 2021 | 4 | |
| 13 | 2023 | 3 | |
| 14 | 2022 | 2 | |
| 15 | 2022 | 2 | |
| 16 | 2020 | 2 | |
| 17 | 2023 | 1 | |
| 18 | 2019 | 1 | |
| 19 | 2012 | 1 | |
| 20 | 2019 | 1 |
About Mok Oh
Mok Oh is a scholar working on Oncology, Surgery, Pulmonary and Respiratory Medicine, Genetics and Economics and Econometrics, having authored 25 papers that have together received 619 indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (6 papers), BRCA gene mutations in cancer (5 papers), Health Systems, Economic Evaluations, Quality of Life (5 papers), Prostate Cancer Diagnosis and Treatment (3 papers), Pancreatic and Hepatic Oncology Research (3 papers), Economic and Financial Impacts of Cancer (2 papers), Radiopharmaceutical Chemistry and Applications (2 papers) and Statistical Methods in Clinical Trials (2 papers). The work is most often cited by research in Gastroenterology (91 citations), Oncology (263 citations), Pulmonary and Respiratory Medicine (300 citations), Neurology (75 citations) and Cancer Research (108 citations). Mok Oh has collaborated with scholars based in United States, Japan and Belgium. Frequent co-authors include Ivo Abraham, Ali McBride, Jennifer Martin, Joanne Jeter, Kohei Shitara, Jung Wook Park, Peter C. Enzinger, Rui‐Hua Xu, Ahsan M. Arozullah and Giuseppe Aprile. Their work appears in journals such as Journal of Clinical Oncology, ESMO Open, JNCI Journal of the National Cancer Institute, Expert Opinion on Drug Safety and The Prostate.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.